BriaCell Therapeutics Corp. (NASDAQ: BCTX), the clinical-stage biotechnology company, recently reported the overall survival benefit of its ongoing advanced breast cancer study. The company released overall survival (OS) data of women under treatment of Bria-IMT™, the company’s lead candidate for monotherapy in breast cancer. Bria-IMT™ is used alongside checkpoint inhibitors […]